And, later this week, Moderna vaccine expected to receive recommendation from FDA advisory panel
TUESDAY, Dec. 15, 2020 (HealthDay News) — The number of Americans killed by COVID-19 topped 300,000 on Monday, the same day the country launched a massive vaccination campaign to curb the spread of COVID-19.
And on Tuesday morning, scientists from the U.S. Food and Drug Administration released a data review that almost guarantees a second vaccine will soon join the Pfizer vaccine that was sent out on Monday: The two-shot Moderna regimen, which is based on the same technology as the Pfizer vaccine, was found to be 94 percent effective in a clinical trial and carried no serious safety concerns. The glowing assessment positions the Moderna vaccine for approval from an FDA advisory panel that is meeting on Thursday, The Washington Post reported.
As the first doses of the Pfizer vaccine made their way to the arms of health care workers around the United States, a new survey from the Kaiser Family Foundation showed that 71 percent of Americans say they will “definitely or probably” get a COVID-19 vaccine.
That is up from 63 percent in September, and it is a sign that a growing number of Americans are starting to trust the science behind the vaccines as they become more comfortable with the speed in which the vaccines are being developed.
~16 Percent of COVID Cases Develop Postacute Sequelae of SARS-CoV-2 
Parts of the World Seeing New COVID-19 Variant 
HHS, NIH Unveil Vaccine Initiative to Protect Against Future Pandemics 
Hospital-Onset SARS-CoV-2 Infection During Omicron Linked to Morbidity 
Staffing, Scheduling, and Wage Changes Could Reattract Nurses Back to Hospitals 
Skilled Nursing Facility Capacity Declined Between 2019 and 2024 
Physical Design of Critical Care Units Influences Nursing Culture 
Low Capability Pediatric Hospitals More Than Doubled From 2003 to 2022 
